A\Prof Nicholas Gough, PhD FTSE MAICD
Key Skills: Biomedical research and cancer biology; Biotechnology Industry; CRC Program
Over 35 years experience in the biotechnology industry, and in the Cooperative Research Centres program, Dr Gough is the inventor of technologies underpinning a number of biopharmaceuticals and biotechnology products, including GM-CSF (sargramostim), one of the first pharmaceuticals based on Australian science and IP, mavrilimumab, under development by AstraZeneca for rheumatoid arthritis, and ESGRO™ used for the maintenance of embryonic stem cells.
Dr Gough holds a number of high profile appointments including Associate Professor (Honorary), Department of Medicine, University of Melbourne; Chair, Research Advisory Committee Wound Management Innovation CRC.
Key past appointments include: Head, Molecular Haematology Laboratory The Walter and Eliza Hall Institute of Medical Research; Research Director AMRAD Corporation Limited; CEO Cerylid Biosciences Limited; CEO Cooperative Research Centre for Genes for Common Human Diseases; Director, Molecular and Genomic Discovery ES Cell International Pte Ltd (Singapore); Chair, Scientific Advisory Board Innovative Dairy Products CRC; Chair, Scientific Advisory Board LactoPharma (New Zealand).
Co-recipient of the 2011 Clunies Ross Medal of the Australian Academy of Technological Sciences and Engineering for the application of science and technology for the benefit of Australia.